Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand and are willing to sign a written consent form before any study procedures begin.
- People who previously took part in a sponsor-run clinical trial that involved a treatment called cadonilimab (also known as AK104), and where that original trial has now finished.
- People who agree to take part in extended follow-up check-ins as part of this study.
- People who are already taking part in other clinical studies at the same time are also eligible, as this study is observational only and does not involve any new treatment.
Who may not be able to join:
- No specific exclusion criteria have been listed for this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jiafu Ji, MD, Peking University Cancer Hospital & Institute
Phone: 86-0760-89873999
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.